The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
NCCTG N057K phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: A North Central Cancer Treatment Group trial.
Daniel Ma
No relevant relationships to disclose
Evanthia Galanis
No relevant relationships to disclose
David Schiff
No relevant relationships to disclose
Wenting Wu
No relevant relationships to disclose
Patrick J. Peller
No relevant relationships to disclose
Caterina Giannini
No relevant relationships to disclose
Paul D. Brown
No relevant relationships to disclose
Joon H. Uhm
No relevant relationships to disclose
Steven McGraw
No relevant relationships to disclose
Kurt A. Jaeckle
No relevant relationships to disclose
Patrick J. Flynn
No relevant relationships to disclose
Jan C. Buckner
No relevant relationships to disclose
Jann Nagina Sarkaria
No relevant relationships to disclose